Optic Neuropathy - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 49 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Optic Neuropathy - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Optic Neuropathy - Pipeline Review, H2 2014', provides an overview of the Optic Neuropathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Optic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Optic Neuropathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Optic Neuropathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Optic Neuropathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Optic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Optic Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Optic Neuropathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Optic Neuropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Optic Neuropathy Overview 6
Therapeutics Development 7
Pipeline Products for Optic Neuropathy - Overview 7
Pipeline Products for Optic Neuropathy - Comparative Analysis 8
Optic Neuropathy - Therapeutics under Development by Companies 9
Optic Neuropathy - Therapeutics under Investigation by Universities/Institutes 10
Optic Neuropathy - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Optic Neuropathy - Products under Development by Companies 13
Optic Neuropathy - Products under Investigation by Universities/Institutes 14
Optic Neuropathy - Companies Involved in Therapeutics Development 15
Inotek Pharmaceuticals Corporation 15
Neurotech Pharmaceuticals, Inc. 16
PharmatrophiX, Inc. 17
Quark Pharmaceuticals, Inc. 18
Optic Neuropathy - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Antibody to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
BA-240 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
NT-501 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
QPI-1007 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
RPh-201 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules for CNS Disorders and Ophthalmology - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Synthetic Peptide to Inhibit Connexin for Optic Neuropathy - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
trabodenoson - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Optic Neuropathy - Recent Pipeline Updates 44
Optic Neuropathy - Dormant Projects 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables
Number of Products under Development for Optic Neuropathy, H2 2014 7
Number of Products under Development for Optic Neuropathy - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Optic Neuropathy - Pipeline by Inotek Pharmaceuticals Corporation, H2 2014 15
Optic Neuropathy - Pipeline by Neurotech Pharmaceuticals, Inc., H2 2014 16
Optic Neuropathy - Pipeline by PharmatrophiX, Inc., H2 2014 17
Optic Neuropathy - Pipeline by Quark Pharmaceuticals, Inc., H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27
Optic Neuropathy Therapeutics - Recent Pipeline Updates, H2 2014 44
Optic Neuropathy - Dormant Projects, H2 2014 47